GREAT POINT PARTNERS LLC

Private Equity

GREAT POINT PARTNERS LLC is a Private Equity based in Greenwich, CT led by Jeffrey Robert Jay, reporting $1.5B in AUM as of Q3 2025 with 85% Healthcare concentration and 66% concentrated in top 10 holdings.

Managing PartnerJeffrey Robert Jay

Portfolio Value: $226.8M
Positions: 27
Top Holding: AMLX at 10.19%
Last Reported: Q3 2025

Address165 Mason Street, 3rd Floor, Greenwich, CT, 06830, United States

Top Holdings

Largest long holdings in GREAT POINT PARTNERS LLC's portfolio (65.6% of total portfolio)

See all holdings

GthenH

Holding	Sector	Position	Weight	Traded	Ownership	Owned Since
1 Amylyx Pharmaceuticals, Inc. AMLX	Biotechnology Healthcare	$23.1M	10.19%	-$4.1M Sold	1.59% 1.7M shares	Q1 2025 Held for 8 months
2 Rezolute RZLT	Biotechnology Healthcare	$23.0M	10.16%	-$5.5M Sold	2.70% 2.5M shares	Q4 2024 Held for 11 months
3 Nektar Therapeutics NKTR	Biotechnology Healthcare	$17.1M	7.53%	+$17.1M Bought	1.58% 300.0K shares	Q3 2025 Held for 2 months
4 Zura Bio Limited ZURA	Biotechnology Healthcare	$16.5M	7.29%	+$2.8M Bought	5.87% 3.8M shares	Q2 2023 Held for 2y 5m
5 Soleno Therapeutics SLNO	Biotechnology Healthcare	$15.2M	6.71%	+$15.2M New	0.42% 225.0K shares	Q3 2025 Held for 2 months
6 ASND Ascendis Pharma ASND	Unknown Unknown	$14.9M	6.57%	+$14.9M Bought	— 75.0K shares	Q2 2025 Held for 5 months
7 Apogee Therapeutics, Inc. APGE	Biotechnology Healthcare	$12.1M	5.33%	+$12.1M Bought	0.51% 304.0K shares	Q3 2025 Held for 2 months
8 Dianthus Therapeutics DNTH	Biotechnology Healthcare	$10.5M	4.61%	+$10.5M Bought	0.67% 265.8K shares	Q1 2024 Held for 1y 8m
9 Cytokinetics CYTK	Biotechnology Healthcare	$8.2M	3.64%	—	0.13% 150.0K shares	Q1 2023 Held for 2y 8m
10 Immunovant, Inc. IMVT	Biotechnology Healthcare	$8.1M	3.55%	+$3.8M Bought	0.29% 500.0K shares	Q1 2025 Held for 8 months

See all holdings

GthenH

Changes

Portfolio activity, position movements, and quarter-over-quarter changes in GREAT POINT PARTNERS LLC's latest filing

See all changes

GthenC

Market Value

$226.8M

Prior: $153.8M

Q/Q Change

+47.45%

+$73.0M

Net Flows % of MV

-16.47%

Turnover Ratio

38.18%

New Purchases

5 stocks

$31.1M

Added To

4 stocks

+$7.8M

Sold Out Of

8 stocks

$30.8M

Reduced Holdings

5 stocks

-$45.4M

Increased Positions

Position	Shares Δ	Change
1 Soleno Therapeutics SLNO	New	0 → 225.0K +$15.2M
2 Eupraxia Pharmaceuticals EPRX	New	0 → 1.2M +$7.1M
3 Pharvaris PHVS	New	0 → 155.1K +$3.9M
4 Sana Biotechnology SANA	New	0 → 700.0K +$2.5M
5 Absci Corporation ABSI	New	0 → 796.4K +$2.4M

Decreased Positions

Position	Shares Δ	Change
1 Akebia Therapeutics AKBA	Sold	2.0M → 0 −$7.2M
2 Evolus EOLS	Sold	720.1K → 0 −$6.6M
3 Arcellx, Inc. ACLX	Sold	100.0K → 0 −$6.6M
4 KalVista Pharmaceuticals KALV	Sold	323.2K → 0 −$3.7M
5 CNTA Centessa Pharmaceuticals CNTA	Sold	225.0K → 0 −$3.0M